Synergistic antibiotic activity against planktonic and biofilm-embedded Streptococcus agalactiae, Streptococcus pyogenes and Streptococcus oralis
暂无分享,去创建一个
[1] C. Perka,et al. High failure rates in treatment of streptococcal periprosthetic joint infection: RESULTS FROM A SEVEN‐YEAR RETROSPECTIVE COHORT STUDY , 2017, The bone & joint journal.
[2] P. Sendi,et al. In vitro activity of gentamicin as an adjunct to penicillin against biofilm group B Streptococcus , 2017, Journal of Antimicrobial Chemotherapy.
[3] C. Hulet,et al. Outcome of patients with streptococcal prosthetic joint infections with special reference to rifampicin combinations , 2016, BMC Infectious Diseases.
[4] A. Trampuz,et al. Activities of Fosfomycin and Rifampin on Planktonic and Adherent Enterococcus faecalis Strains in an Experimental Foreign-Body Infection Model , 2013, Antimicrobial Agents and Chemotherapy.
[5] B. Henriques-Normark,et al. Increased incidence of invasive group A streptococcal infections in Sweden, January 2012-February 2013. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[6] P. Choong,et al. Management of Prosthetic Infection According to Organism , 2013 .
[7] S. Shukla,et al. Dispersal of Bap-mediated Staphylococcus aureus biofilm by proteinase K , 2012, The Journal of Antibiotics.
[8] S. Cardona,et al. Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci , 2011, The Journal of Antibiotics.
[9] K. Boggian,et al. Group B streptococcus in prosthetic hip and knee joint-associated infections. , 2011, The Journal of hospital infection.
[10] James J. Collins,et al. Metabolite-Enabled Eradication of Bacterial Persisters by Aminoglycosides , 2011, Nature.
[11] C. Malone,et al. Biofilm dispersal of community‐associated methicillin‐resistant Staphylococcus aureus on orthopedic implant material , 2010, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[12] M. Lavigne,et al. Group B streptococcal prosthetic joint infections: a retrospective study of 30 cases. , 2009, Presse medicale.
[13] M. Falagas,et al. Susceptibility of Urinary Tract Bacteria to Fosfomycin , 2009, Antimicrobial Agents and Chemotherapy.
[14] D. Wirz,et al. Isothermal micro calorimetry – a new method for MIC determinations: results for 12 antibiotics and reference strains of E. coli and S. aureus , 2009, BMC Microbiology.
[15] J. Greenleaf,et al. Sonication of removed hip and knee prostheses for diagnosis of infection. , 2007, The New England journal of medicine.
[16] Á. Pascual,et al. In Vitro Activity of Fosfomycin against Extended-Spectrum-β-Lactamase- Producing Escherichia coli and Klebsiella pneumoniae: Comparison of Susceptibility Testing Procedures , 2006, Antimicrobial Agents and Chemotherapy.
[17] W. Zimmerli,et al. Prosthetic joint infections: update in diagnosis and treatment. , 2005, Swiss medical weekly.
[18] Ronald N. Jones,et al. Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. , 2005, The Journal of antimicrobial chemotherapy.
[19] W. Zimmerli,et al. Prosthetic-joint infections. , 2004, The New England journal of medicine.
[20] D. Murdoch,et al. Successful antimicrobial therapy and implant retention for streptococcal infection of prosthetic joints , 2004, ANZ journal of surgery.
[21] H. Kennedy,et al. Antimicrobial susceptibility of viridans group streptococcal blood isolates to eight antimicrobial agents , 2004, Scandinavian journal of infectious diseases.
[22] F. Odds,et al. Synergy, antagonism, and what the chequerboard puts between them. , 2003, The Journal of antimicrobial chemotherapy.
[23] A. Widmer. New developments in diagnosis and treatment of infection in orthopedic implants. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] M. Farley. Group B streptococcal disease in nonpregnant adults. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] W. Traub,et al. Antibiotic susceptibility of alpha- and nonhemolytic streptococci from patients and healthy adults to 24 antimicrobial drugs. , 1997, Chemotherapy.
[26] F. Lowy,et al. Penicillin-induced effects on streptomycin uptake and early bactericidal activity differ in viridans group and enterococcal streptococci , 1986, Antimicrobial Agents and Chemotherapy.
[27] D. Goldmann,et al. In vitro activity of penicillin and rifampin against group B streptococci. , 1983, Reviews of infectious diseases.
[28] F. Lowy,et al. Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci , 1983, Antimicrobial Agents and Chemotherapy.
[29] C. Norden. Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin. , 1975, The Journal of infectious diseases.
[30] R. Moellering,et al. Synergy of penicillin and gentamicin against Enterococci. , 1971, The Journal of infectious diseases.
[31] M. Di Luca,et al. Detection of Biofilms in Biopsies from Chronic Rhinosinusitis Patients: In Vitro Biofilm Forming Ability and Antimicrobial Susceptibility Testing in Biofilm Mode of Growth of Isolated Bacteria. , 2018, Advances in Experimental Medicine and Biology.
[32] C. Doern,et al. Biofilm formation by group A Streptococcus: a role for the streptococcal regulator of virulence (Srv) and streptococcal cysteine protease (SpeB). , 2009, Microbiology.
[33] D. Vinh,et al. Device-related infections: a review. , 2005, Journal of long-term effects of medical implants.